Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (1192)	3/2/1998 11:58:00 PM
From: D.Right	Read Replies (1) \| Respond to of 2173

It didn't take too long to have Henry back to predict all the price actions once we had some bad news. Sure it is bad news, but not as bad as Henry would like. With JNJ given up all the right for pramlintide, AMLN can easily find another partner. And I think AMLN must do that because to market a drug for diabetes is a major undertaking. However, with the big chunk development cost paid by JNJ already for free, AMLN can sign a partner on an even better term than the one they did with JNJ. So far, the only input JNJ had was money, AMLN does not need other help before they start marketing. Also, the decision to file for European approval in first half of 1999 for type I indication is a good one. It may cost more money in the long run to file twice (type II later), but it will lead AMLN to profitability one year earlier. It is a smart business decision considering the current situation. Tomorrow AMLN's price will fall, but I think Henry will be surprised at the support level we will have. Let's see. It is less than 10 hours now. Good night everyone. D.Right